<DOC>
	<DOC>NCT01399593</DOC>
	<brief_summary>The purpose of this trial is to determine the safety and efficacy of eculizumab in the prevention of antibody mediated rejection (AMR) in living donor kidney recipients requiring desensitization therapy.</brief_summary>
	<brief_title>Safety &amp; Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization</brief_title>
	<detailed_description />
	<criteria>1. Male or female patients â‰¥18 years old 2. Patients with Stage IV or Stage V chronic kidney disease who will receive a kidney transplant from a living donor to whom they are sensitized and require desensitization prior to transplantation 3. Able to understand the informed consent form and willing to comply with study procedures 1. Hypersensitivity to eculizumab, to murine proteins or to one of the excipients 2. Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confounds the assessment of the patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Antibody Mediated Rejection</keyword>
	<keyword>AMR</keyword>
	<keyword>Acute Humoral Rejection</keyword>
	<keyword>AHR</keyword>
	<keyword>Living Donor</keyword>
	<keyword>Kidney Transplant</keyword>
</DOC>